Does Dr. MARIO GASPAR DE ALBA have financial conflicts of interest?

Dr. MARIO GASPAR DE ALBA (M.D.) has received a total of $234 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $234 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MARIO GASPAR DE ALBA?

According to CMS Open Payments data, Dr. MARIO GASPAR DE ALBA received funding from ARCUTIS BIOTHERAPEUTICS ($137), TRIS PHARMA ($48), and AVADEL CNS PHARMACEUTICALS ($20).

Does Dr. MARIO GASPAR DE ALBA receive research grants or speaking fees?

Dr. MARIO GASPAR DE ALBA has received $234 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MARIO GASPAR DE ALBA

M.D.Real-Time Hydrated

Specialty: Pediatrics, Developmental - Behavioral Pediatrics

Practice Location: LAS VEGAS, NV 89106

NPI Number: 1275546590

LIFETIME INDUSTRY VALUE

$234

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. GASPAR DE ALBA is a verified Pediatrics, Developmental - Behavioral Pediatrics practitioner based in LAS VEGAS, NV.

Between 2021 and 2025, Dr. GASPAR DE ALBA had an overall industry promotional and research financial footprint of $234 as recorded in the federal CMS Open Payments database.

$234 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. GASPAR DE ALBA's primary funding source is ARCUTIS BIOTHERAPEUTICS, which accounts for $137 (representing 58.7% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ARCUTIS BIOTHERAPEUTICS

Rank 1

$137

58.7%

TRIS PHARMA

Rank 2

$48

20.4%

AVADEL CNS PHARMACEUTICALS

Rank 3

$20

8.4%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.